VIENNA — Success with the first autologous transplantation of iPS-RPE sheets opens a new frontier in the treatment of age-related macular degeneration.Masayo Takahashi, MD, PhD, keynote lecturer at the meeting of the European Society of Ophthalmology, approached the concept of stem cells at the Salk Institute in 1995 and pioneered research on stem cell transplantation into the retina.
Leica agrees to acquire Bioptigen
Leica Microsystems intends to acquire Bioptigen Inc. “to strengthen its position in the ophthalmology market,” the company announced in a press release after a definitive agreement between the two was signed.Leica develops and manufactures microscopes and scientific instruments; Bioptigen develops and manufactures OCT technology.
Advances in Drug Delivery to the Posterior Segment
What emerging drug delivery technologies are on the horizon for vitreoretinal diseases, and how do they perform in terms of safety and efficacy? Current Opinion in Ophthalmology
Intraoperative OCT enhances safety, accuracy of peeling surgery
VIENNA — Intraoperative OCT has the potential to make peeling surgery easier and safer, offering real-time visualization of surgical maneuvers and iatrogenic effects of peeling-associated traction, according to one surgeon. In a study set up by the group of Oliver Findl, MD, at Hanusch Hospital in Vienna, the Rescan 700 OCT system (Carl Zeiss Meditec) was used during 23-gauge pars plana vitrectomy with membrane peeling in 20 patients.
Samenvatting: LENSAR krijgt CE-markering voor vijf upgrades van LENSAR Laser System
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR Inc., wereldleider in femtosecondelasertechnologie voor de operatie van hardnekkige grijze staar, heeft vandaag bekendgemaakt dat het een CE-markering heeft gekregen van de Europese Unie voor een reeks van vijf to…
Resumen: LENSAR recibe marcado CE para cinco nuevas actualizaciones de las prestaciones de las aplicaciones para el sistema láser LENSAR
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc., líder mundial en tecnología láser femtosegundo de próxima generación para la cirugía refractiva de cataratas, ha anunciado hoy que ha recibido el marcado CE de los organismos de la Unión Europea para una gama de cinco nuevas tecnologías de aplicaciones en el producto insignia de la compañía, el sistema láser LENSAR®. El comunicado en el idioma original, es la versión oficial y autorizada del mismo. La traducción es solamente un medio de ayuda y debe